Citations |
Autophagy. 2024 May 18. Biochem Biophys Res Commun. 2024 Feb 15, 149661. bioRxiv. 2024 Dec 8:2024.12.07.627371. bioRxiv. 2024 September 23. Cancer Immunol Res. 2024 Jul 11. Cancer Med. 2023 Jun 7. Chem Biol Drug Des. 2023 Nov;102(5):1110-1120. Chem Eng J. 2021 Aug 15;418:129392. Clin Cosmet Investig Dermatol. 2024 May 14:17:1093-1105. Clin Transl Med. 2024 Sep;14(9):e70027. Curr Microbiol. 2024 Aug 6;81(9):296. FASEB J. 2024 Mar 31. Res Sq. 2024 Nov 14. SSRN. 2023 Apr 29. Vet Res. 2024 Sep 27;55(1):115. Virol Sin. 2023 Aug 24;S1995-820X(23)00104-9. Virol Sin. 2023 May 2;S1995-820X(23)00048-2. Adv Funct Mater. 29 August 2022. Liver Int. 2022 Oct 17. Mol Ther Oncolytics. 25 August 2022. Phytomedicine. 2021, 153495. SSRN. 2021 Apr 26. [1]Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-738. [2]Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002;293(5):1364-1369. [3]Cheng Y, Xu F. Anticancer function of polyinosinic-polycytidylic acid [J]. Cancer biology & therapy, 2010, 10(12): 1219-1223. [4]Deleidi M, Hallett P J, Koprich J B, et al. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration [J]. Journal of Neuroscience, 2010, 30(48): 16091-16101. [5]Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer [J]. The Journal of Immunology, 2012, 188(11): 5357-5364. [6]Rezaee F, Meednu N, Emo J A, et al. Polyinosinic: polycytidylic acid induces protein kinase D–dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells [J]. Journal of Allergy and Clinical Immunology, 2011, 128(6): 1216-1224. e11. [7]Wang P F, Fang H, Chen J, et al. Polyinosinic-polycytidylic acid has therapeutic effects against cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via TLR3 [J]. The Journal of Immunology, 2014, 192(10): 4783-4794. |